BioAgilytix expands global bioanalytical capabilities with new Sydney laboratory. Tuesday, October 13, 2026 BioAgilytix, a global leader in bioanalytical services, announces the opening of a new laboratory in North Ryde, Sydney, through 360biolabs, its Australian laboratory business. The expansion extends BioAgilytix's bioanalytical footprint across Australia, Europe and the United States. The laboratory is located in Sydney's Macquarie Park Innovation District, a major New South Wales science, health and technology precinct near clinical trial units, hospitals, research organizations and participant populations. With locations in Melbourne, Brisbane and Sydney, 360biolabs gives sponsors access to bioanalytical support across Australia's eastern states, where much of the country's clinical research infrastructure and population base is concentrated. The Sydney laboratory has been purpose-built for time-sensitive clinical trial samples and complex early-phase study requirements. Initial capabilities in the BSL-2 laboratory space include PBMC isolation, flow cytometry, sample reception and storage, ULT freezer capacity, vapour-phase nitrogen cryostorage, and 24/7 temperature monitoring. For sponsors planning first-in-human and early clinical studies, the expansion supports a practical development model: generate early data in Australia, then maintain scientific and operational continuity as programs advance into later-phase global development. "Australia is a primary destination for early-phase clinical research, supported by a streamlined regulatory pathway, rapid study start-up timelines and R&D tax incentives for eligible sponsors," said Davide Molho, CEO of BioAgilytix. "The new Sydney laboratory expands BioAgilytix's Australian footprint through 360biolabs, alongside Melbourne and Brisbane, and strengthens our ability to support sponsors as their programs advance across global regions." Australia can support efficient early-phase clinical study execution through its recognised quality standards, practical regulatory environment, cost efficiency for eligible sponsors and data utility when studies are conducted to accepted requirements. The Sydney expansion reinforces BioAgilytix's ability to support sponsors seeking a coordinated pathway from first-in-human studies through global development. "Sydney allows us to invest alongside the growth in Australia's clinical trials infrastructure. It expands our ability to support clients locally, strengthens our national business and creates a stronger foundation for continued growth in the region." said Alistair Draffan, President of 360biolabs. 360biolabs is accredited by Australia's National Association of Testing Authorities (NATA) for compliance with Good Laboratory Practice (GLP), Good Clinical Laboratory Practice (GCLP), and ISO/IEC 17025. This accreditation supports sponsors seeking recognised quality standards for early-phase studies conducted in Australia. The Sydney laboratory extends BioAgilytix's global network and strengthens its ability to support sponsors with local expertise and continuity across regions as programs progress. About 360biolabs 360biolabs is Australia's most comprehensive bioanalytical laboratory, supporting the development of therapeutics, vaccines and diagnostics. With laboratories in Melbourne, Brisbane and Sydney, 360biolabs supports clinical studies across PK, PD, immunogenicity, biomarkers, vaccines, infectious diseases, flow cytometry, molecular biology and central laboratory services. 360biolabs is accredited by Australia's National Association of Testing Authorities (NATA) for compliance with Good Laboratory Practice (GLP), Good Clinical Laboratory Practice (GCLP), and ISO/IEC 17025. About BioAgilytix BioAgilytix is a global bioanalytical laboratory partner supporting biopharmaceutical and biotechnology companies across every phase, every modality. Through its global laboratory network in Australia, the United States and Europe, BioAgilytix provides integrated scientific and operational support for complex clinical development programs. Media Contact Bernice Averion Marketing and Communications Manager, 360biolabs [email protected]

BioAgilytix celebrates Jessica Bridges Weaver for scientific leadership with 2026 TBJ Award. Durham, N.C. - March 24, 2026 - BioAgilytix, a global leader in bioanalytical services, is proud to celebrate its commitment to scientific excellence and leadership with Jessica Bridges Weaver, Scientific Officer, who has been named a 2026 Triangle Business Journal Women in Business Award Winner. With more than 20 years of experience across pharmaceutical manufacturing and analytical testing, Jessica has played a critical role in strengthening BioAgilytix's scientific and regulatory leadership. In her role, she partners closely with global laboratory and business development teams to advise clients on phase-appropriate, regulatory-ready testing strategies for complex biologics. Her work extends to assay design and troubleshooting, ensuring methods align with both client objectives and evolving global regulatory expectations. Her impact has been especially evident in the strategic expansion of BioAgilytix's CMC analytical testing services in the Research Triangle Park hub, as well as the global growth of GMP bioassay capabilities and the development of specialized infrastructure in Hamburg, Germany. Beyond operational leadership, Jessica is a recognized thought leader in CMC analytics and bioanalysis who produces and delivers webinars, conference presentations, and peer-reviewed publications that promote continuous learning and knowledge-sharing across the life sciences community. "Jessica exemplifies the scientific rigor, integrity, and collaborative leadership that defines BioAgilytix," said Davide Molho, Chief Executive Officer of BioAgilytix. "Her ability to translate complex science into meaningful impact for our clients and the industry makes her an outstanding leader and a deserving recipient of this recognition." In addition to her professional achievements, Jessica is deeply committed to community service and mentorship. She actively supports STEM education initiatives, mentors high school students, and partners with organizations focused on pediatric care and child welfare. Her work reflects a lifelong commitment to stewardship, integrity, and expanding access to opportunities for future generations. "It is truly an honor to be recognized alongside so many inspiring women," said Jessica Weaver. "This recognition reflects the incredible teams I am privileged to work with at BioAgilytix and our shared commitment to advancing science, strengthening communities, and improving patients' lives. I am grateful for the opportunity to contribute to work that creates meaningful impact for our clients and the broader life sciences community." Jessica's recognition represents the strength of the BioAgilytix community, and a culture built on collaboration, integrity, and scientific excellence. About BioAgilytix BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.